Home
Transactions

Work Area: Transactions

Your guide to synthetic drug royalty dealmaking

Selling revenue streams is an increasingly important way of monetising pharma innovations

Five key patent transactions takeaways

An over-arching theme during an IAM event was the key importance of relationships, trust and empathy between parties when deals are getting done

WiLAN revenues plummet in Q3 on prior year but Micron deal excluded

Strategic review of the licensing business nears a year in motion with no news on potential divestment announced

Latest content

Drug royalty agreements can help Big Pharma overcome patent cliffs, says top dealmaker

Behzad Khosrowshahi, CEO of DRI Healthcare Trust, looks at recent deals the firm has done, explains what makes a transaction attractive and how to get one over the line

04 November 2022

France Brevets’ public sector links hindered monetisation efforts, says CEO

As the sovereign patent fund closes down, CEO Didier Patry shares his thoughts with IAM readers on the organisation’s work over the past decade

03 November 2022

IP finance, monetisation and much more take centre stage on Day One of IPBC Asia 2022

A broad range of subjects and talking points - including a plenary address from JPO Commissioner Koichi Hamano - kept the 400+ delegates engaged as the event got underway in Tokyo

01 November 2022

BlackBerry has ‘lost the signal’ … again

The series of missteps and errors in the Canadian company’s struggling patent portfolio sale offers a cautionary tale to any IP owner emulating this in future

29 October 2022

Myovant $2.9 billion buyout is the product of smart IP deal-making

The company’s high value was produced by a series of innovative patent transactions

27 October 2022

Trademarks and brands: key considerations for M&A transactions

It is crucial that a buyer or seller of a company does not overlook trademarks and brands in business acquisitions, or any red flags in that area. Luckily, there are solutions to overcome such complexities.

26 October 2022

US patent allowance crucial to $566 million Aveo Oncology buyout

Success at the USPTO clinched a premium-price acquisition for the oncology innovator

25 October 2022

Drug royalty sales supercharged by sinking biotech valuations, says leading dealmaker

Following the firm’s recent $115 million investment, Sagard Healthcare Royalty Partners’ Ali Alagheband says a flurry of activity is underway in the market

03 October 2022

Takeda continuing divestment spree by monetising unwanted oncology IP

The Japanese company is leading the pack in trend of commercialising de-prioritised assets

30 September 2022

BlackBerry hints at restart for licensing business as patent sale stalls

CEO John Chen tells investors that plans to rebuild the in-house operation are being finalised but says he remains confident a deal with Catapult IP will be done

29 September 2022

Unlock unlimited access to all IAM content